Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

19.03.2025

Oxford BioTherapeutics Announces That Partner Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments

09.01.2025

Oxford BioTherapeutics To Present at World ADC Conference 2024

30.10.2024

Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024

22.07.2024

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

07.03.2024

Oxford BioTherapeutics Announces First Patient Dosed With OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

18.01.2024

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

29.11.2023

Oxford BioTherapeutics Announced Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial With BI 764532 in Small Cell Lung Cancer and Other Neuroendocrine Cancers

24.10.2023

Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at the Oxford Science Park To Accelerate Development of Its Immuno-Oncology and ADC-Based Cancer Therapies

11.10.2023

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers​

03.10.2023

Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim's upcoming Transforming Science Day: Europe ​​

19.09.2023

Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumours by Dosing First Patient in Combination with CPI Balstilimab in Europe ​

05.07.2023

Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

25.05.2023

Oxford BioTherapeutics Announces Phase1b Trial in Collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the Head and Neck

19.04.2023

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023

09.03.2023

Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards

07.03.2023